NCT06056570View on ClinicalTrials.gov

Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 4, 2023

Primary Completion Date

June 27, 2024

Study Completion Date

July 9, 2024

Conditions
GoutHyperuricemia
Interventions
DRUG

dontinurad

dotinurad alone

DRUG

dotinurad + allopurinol

dotinurad + allopurinol 300mg

DRUG

allopurinol

allopurinol 300 mg alone

Trial Locations (4)

33014

Panax Clinical Research, Miami Lakes

33765

Clinical Research of West Florida, Clearwater

75150

Southwest Rheumatology Research, Mesquite

78240

Endeavor Clinical Trials, San Antonio

All Listed Sponsors
lead

Urica Therapeutics Inc.

INDUSTRY

NCT06056570 - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia | Biotech Hunter | Biotech Hunter